deCODE Chemistry and FSMA Announce Extension of Research Agreement
News Jan 17, 2006
Initiated in 2003, the deCODE chemistry-FSMA collaboration focused on optimization of a class of molecule that was discovered in a high-throughput, cell-based phenotypic assay developed under sponsorship by FSMA.
The focus of the collaboration in the coming year will be to further assess the pharmaceutical properties of lead candidates and select a small number of analogues for IND-directed, pre-clinical development.
"We are pleased to continue our collaboration with FSMA on this important program," said Dr. David Zembower, Vice President of Chemistry at deCODE chemistry.
"We are encouraged by the progress that has been made over the past year, and look forward to working with FSMA to help them achieve their goals."
"There has been much progress in SMA research since our relationship with deCODE began, and we are proud that our collaborative effort has been a part of that," said Dr. Jill Jarecki, FSMA Research Director.
"We are confident that our pioneering endeavor has the potential to enable a novel treatment for SMA."
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE